Search: onr:"swepub:oai:gup.ub.gu.se/56077" >
Impact of age on le...
Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study)
- Article/chapterEnglish2004
Publisher, publication year, extent ...
Numbers
-
LIBRIS-ID:oai:gup.ub.gu.se/56077
-
https://gup.ub.gu.se/publication/56077URI
Supplementary language notes
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
To assess the influence of age on changes in left ventricular (LV) mass and geometry during antihypertensive treatment, we related age to clinical and echocardiographic findings before and after 4 years of antihypertensive treatment in a subset of 560 hypertensive patients without known concurrent disease in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, which randomized patients to blinded losartan- or atenolol-based treatment. Patients >/=65 years (older group) included more women and patients with isolated systolic hypertension or albuminuria (all P<0.05). Compared to patients <65 years, older patients had higher pulse pressure, LV mass, and prevalence of concentric hypertrophy at baseline (78 vs 69 mmHg, 234 vs 224 g, and 28 vs 16%, respectively, all P<0.01), while the mean blood pressure did not differ. Over 4 years, reductions in LV mass and the mean blood pressure were similar in both groups, but older patients more often had residual hypertrophy (31 vs 15%, P<0.001) with a preponderance of eccentric geometry. In multivariate analysis of 4-year change in LV mass controlling for baseline mass, larger hypertrophy reduction was associated with losartan treatment, while age, gender, body mass index, and 4-year change in pulse pressure and albuminuria did not enter (Multiple R (2)=0.40, P<0.001). Thus, in up-to-80-year-old hypertensive patients with left ventricular hypertrophy, age did not significantly attenuate hypertrophy reduction during antihypertensive treatment, although residual hypertrophy was more prevalent in older patients as a consequence of higher initial LV mass.
Subject headings and genre
-
Age Factors
-
Aged
-
Aged
-
80 and over
-
Antihypertensive Agents/*therapeutic use
-
Atenolol/*therapeutic use
-
Female
-
Follow-Up Studies
-
Heart Ventricles/ultrasonography
-
Humans
-
Hypertension/drug therapy
-
Hypertrophy
-
Left Ventricular/drug therapy/*ultrasonography
-
Losartan/*therapeutic use
-
Male
-
Middle Aged
-
Remission Induction
-
Time Factors
Added entries (persons, corporate bodies, meetings, titles ...)
-
Roman, M. J.
(author)
-
Palmieri, V.
(author)
-
Wachtell, K.
(author)
-
Smith, G.
(author)
-
Nieminen, M. S.
(author)
-
Dahlöf, Björn,1953Gothenburg University,Göteborgs universitet,Hjärt-kärlinstitutionen,Cardiovascular Institute(Swepub:gu)xdahbj
(author)
-
Devereux, R. B.
(author)
-
Göteborgs universitetHjärt-kärlinstitutionen
(creator_code:org_t)
Related titles
-
In:J Hum Hypertens18:6, s. 417-220950-9240
Internet link
Find in a library
To the university's database